Table 2. Changes in rhinitis/eye symptoms and clinical scores in the study period between the treatment and control groups.
| Variables | Treatment group | P value* | Control group | P value* | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| V1 | V3 | V4 | V5 | V1 | V3 | V4 | V5 | |||
| Nasal symptoms | 8 (5–10) | 2 (0–7) | 2 (0–8) | 2.5 (0–7) | < 0.001 | 8 (6–10) | 1 (0–8) | 3 (0–6) | 2 (0–5) | < 0.001 |
| Eye symptoms | 2 (0–4) | 0.5 (0–4) | 0.5 (0–5) | 1 (0–5) | 0.036 | 1 (0–4) | 1 (0–4) | 1 (0–5) | 0 (0–5) | 0.363 |
| RTSS | 10 (8–12) | 3 (0–8) | 3 (0–12) | 4 (0–9) | < 0.001 | 9 (8–13) | 2 (0–12) | 3 (0–10) | 3 (0–10) | < 0.001 |
| RQLQ | 54.5 (32–95) | 48 (34–76) | 53.5 (30–87) | 50 (33–75) | 0.053 | 59 (31–84) | 38 (28–84) | 45 (28–78) | 42 (28–94) | 0.077 |
| RCAT | 21.5 (14–27) | 23 (16–30) | 22 (19–30) | 22.5 (16–28) | 0.105 | 22 (17–29) | 25 (16–30) | 22 (13–30) | 23 (17–30) | 0.528 |
| ACT | 21 (13–24) | 20.5 (9–24) | 19.5 (14–25) | 21 (13–24) | 0.841 | 19.5 (14–25) | 22.5 (11–25) | 21 (12–25) | 22 (14–25) | 0.469 |
All values were presented as median (minimum–maximum values).
RTSS, rhinoconjunctivitis total symptom score; RQLQ, rhinoconjunctivitis quality of life questionnaire; ACT, asthma control test; RCAT, rhinitis control assessment test, V, visit.
*Wilcoxon-signed rank test comparing scores between V1 and V5.